Votrient (Renal Cell Carcinoma) – Analysis and Forecasts to 2022 provides Votrient sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from databases, primary and secondary research using SEC filings, investor presentations and featured press releases, both...
View full press release